A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT05948865

Public ClinicalTrials.gov record NCT05948865. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 12:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors

Study identification

NCT ID: NCT05948865
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Enrollment: 132 participants

Conditions and interventions

Conditions

Interventions

CPO301 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 5, 2023
Primary completion: Apr 30, 2027
Completion: Jul 31, 2027
Last update posted: Mar 19, 2026

2023 – 2027

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 11

Facility	City	State	ZIP	Site status
USC Norris Comprehensive Cancer Center	Los Angeles	California	90033	Recruiting
Hoag Memorial Hospital Presbyterian	Newport Beach	California	92658	Recruiting
UCLA Hematology/Oncology - Santa Monica	Santa Monica	California	90404	Recruiting
Sarah Cannon Research Institute (SCRI) at HealthONE	Denver	Colorado	80218	Recruiting
AdventHealth Cancer Institute	Celebration	Florida	34747	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232	Recruiting
Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire	03756	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
NEXT Dallas	Dallas	Texas	75039	Recruiting
NEXT Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05948865, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 19, 2026 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05948865 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →